

International Consensus Study of Antipsychotic Dosing

David M. Gardner, Pharm.D.,
M.Sc.

Andrea L. Murphy, Pharm.D.

Heather O'Donnell, B.Sc. Pharm.

Franca Centorrino, M.D.

Ross J. Baldessarini, M.D.

Objective: Potency equivalents for antipsychotic drugs are required to guide clinical dosing and for designing and interpreting research studies. Available dosing guidelines are limited by the methods and data from which they were generated.

Method: With a two-step Delphi method, the authors surveyed a diverse group of international clinical and research experts, seeking consensus regarding antipsychotic dosing. The authors determined median clinical dosing equivalents and recommended starting, target range, and maximum doses for 61 drugs, adjusted for selected clinical circumstances.

Results: Participants (N=43) from 18 countries provided dosing recommendations regarding treatment of psychotic disorders for 37 oral agents and 14 short-

acting and 10 long-acting parenteral agents. With olanzapine 20 mg/day as reference, estimated clinical equivalency ratios of oral agents ranged from 0.025 for sulpiride to 10.0 for trifluoperidol. Seventeen patient and treatment characteristics, including age, hepatic and renal function, illness stage and severity, sex, and diagnosis, were associated with dosing modifications.

Conclusion: In the absence of adequate prospective, randomized drug-drug comparisons, the present findings provide broad, international, expert consensus-based recommendations for most clinically employed antipsychotic drugs. They can support clinical practice, trial design, and interpretation of comparative antipsychotic trials.

(*Am J Psychiatry* 2010; 167:686–693)

Clinical management of antipsychotic drug treatment is increasingly complex, with growing numbers and applications of clinically employed agents, inconclusive findings among treatment efficacy and effectiveness trials involving first- or second-generation antipsychotic drugs, and polytherapy with complex drug combinations (1–12). Despite growing clinical and research requirements for reliable dosing estimates, available dosing guidelines rest on an inadequate research base (2, 13–18). Proposed schemes usually are based on averages of doses recommended by manufacturers and approved by regulatory bodies or on expert-estimates of approximate clinically equivalent potency (2, 13, 19). It would be desirable to base such potency comparisons on randomized, especially head-to-head, comparisons of a range of antipsychotics at several fixed doses, and across various diagnostic, illness severity, comorbidity, and demographic variables. However, currently available information arising from research of this kind is severely limited, and such studies remain rare (17, 20, 21). Uncertainties about clinically equivalent doses of antipsychotics probably contribute to apparent variance in efficacy and tolerability in clinical practice and to inconsistent findings among experimental clinical trials (4, 5, 22–25).

Given the unsatisfactory evidence base to define clinically equivalent doses and dosing range recommenda-

tions of available antipsychotics for both clinical and research applications, we used a Delphi method (26, 27) of consensus building in a broad, two-stage, questionnaire-based survey of research and clinical experts. We aimed to develop an internationally representative set of clinically equivalent dosing estimates and dosing recommendations for most clinically employed first- and second-generation antipsychotic drugs.

Method

Participants

We identified colleagues with experience in clinical research and in the clinical use of antipsychotic drugs, based on preliminary literature searches, reputation among peers, and by investigator consensus. We sought geographically and demographically diverse participation. Research experts were considered eligible only if they had at least five peer-reviewed publications related specifically to clinical trials of antipsychotic drugs. Clinical experts were referred by participating research experts as particularly knowledgeable in the use of antipsychotic medicines, with extensive clinical practice experience.

Survey

The survey instrument included three sections: [A] clinically equivalent doses; [B] dosing recommendations; and [C] dosing adjustments for specific, defined, circumstances. In section A, participants were to estimate the clinically equivalent

This article is featured in this month's AJP **Audio**, is the subject of a **CME** course (p. 727), and is discussed in an editorial by Dr. Remington (p. 623).

TABLE 1. Clinical Dosing Equivalencies and Dosing Recommendations of Oral Antipsychotics

		Clinically Equivalent Dose ^a (mg/day)					Recommended Dosing (mg/day) ^b					
							Starting Dose		Target Dose	Maximum Dose		
		Equivalency Ratio										
Drug	N	Median	IQR	Confidence	Versus Olanzapine	Versus Chlorpromazine	Median	IQR	Range	Median	IQR	
Amisulpride	29	700	100	M	0.029	0.86	100	50	400–800	1000	200	
Aripiprazole	39	30	5	M	0.67	20.0	10	2.5	15–30	30	0.0	
Benperidol	9	5.0	0.75	L	4.00	120	0.5	0.4	1.0–3.0	3.5	2.0	
Chlorpromazine	38	600	50	M	0.033	1.00	100	25	300–600	800	62	
Clopendthixol	9	60	18.5	L	0.330	10.0	17.5	8.1	22–90	138	34	
Clorprothixene	10	500	125	M	0.040	1.20	50	42	200–400	600	250	
Clotiapine	7	100	20	M	0.200	6.00	40	0.0	100–120	240	50	
Clozapine	38	400	62	H	0.050	1.50	25	6.0	200–500	800	50	
Droperidol	7	10	0.0	M	2.00	60.0	3.0	1.6	4.5–8.8	12.0	2.5	
Flupenthixol	22	10	1.0	M	2.00	60.0	3.0	0.0	5.0–12	18	4.0	
Fluphenazine	27	12	2.5	M	1.67	50.0	3.0	1.5	5.0–15	20	6.5	
Haloperidol	43	10	1.0	H	2.00	60.0	3.0	1.5	5.0–10	20	4.0	
Levomepromazine	22	400	100	M	0.050	1.50	50	25	150–400	500	75	
Loxapine	12	60	22	M	0.330	10.0	17.5	7.0	20–100	200	19	
Mesoridazine	13	300	50	M	0.067	2.00	25	6.0	100–250	400	62	
Methotrimeprazine	6	300	12	L	0.067	2.00	50	0.0	100–300	500	250	
Molindone	9	100	15	L	0.200	6.00	22.5	7.0	50–188	225	12	
Olanzapine	41	20 (ref)	—	—	1.00	30.0	5.0	2.5	10–20	30	0.0	
Oxypertine	5	240	35	L	0.83	2.50	40	18	80–150	200	90	
Paliperidone	19	9.0	0.5	M	2.22	66.7	3.0	0.4	6.0–9.0	12	1.5	
Pericyazine	4	50	0.0	L	0.40	12.0	20	3.8	20–50	60	9.5	
Perphenazine	34	30	4.0	M	0.67	20.0	8.0	1.5	12–24	42	13	
Pimozide	33	8.0	1.5	M	2.50	75.0	2.0	0.5	4.0–6.0	10	0.5	
Prochlorperazine	8	88	36	L	0.230	6.86	15	0.0	15–48	90	15	
Quetiapine	43	750	75	H	0.027	0.80	100	25	400–800	1000	162	
Remoxipride	6	212	50	L	0.094	2.82	75	0.0	112–225	225	75	
Risperidone	43	6.0	0.5	H	3.33	100	2.0	0.5	4.0–6.0	8.5	1.0	
Sertindole	15	20	0.0	M	1.00	30.0	4.0	2.0	12–20	22	2.0	
Sulpiride	28	800	88	M	0.025	0.75	100	50	300–600	1000	200	
Thioridazine	32	500	69	M	0.040	1.20	88	25	200–500	800	100	
Thiothixene	16	30	5.0	M	0.670	20.0	6.0	1.5	15–30	40	7.5	
Trifluoperazine	29	20	6.0	M	1.00	30.0	5.0	0.0	10–20	35	38	
Trifluoperidol	3	2.0	0.0	L	10.0	300	1.0	0.0	1.0–3.0	3.0	0.0	
Triflupromazine	3	100	0.0	L	0.20	6.00	10	0.0	22–125	150	0.0	
Ziprasidone	35	160	5.0	M	0.125	3.75	40	10	120–160	200	40	
Zotepine	14	300	81	M	0.067	2.00	50	12	100–300	400	75	
Zuclopenthixol	25	50	14	M	0.400	12.0	20	5.0	20–60	80	20	

^a Respondents were asked what dose they consider to be clinically equivalent to 20 mg/day of olanzapine in treatment of the reference case, a moderately symptomatic adult man with DSM-IV schizophrenia with ≥ 2 years of antipsychotic treatment and not considered treatment refractory. Median confidence levels for the clinically equivalent doses are reported as low (L), moderate (M), or high (H).

^b Respondents were asked to indicate their usual starting dose, target dosing range, and maximum daily dose for the reference case after being untreated for over 1 month. The target dose range reflects the median lower and upper doses of ranges recommended.

lent dose of 59 antipsychotic preparations, including 36 orally administered agents and 13 short-acting and 10 long-acting injected agents. Clinical scenarios used olanzapine, 20 mg/day, as the reference treatment for the equivalency estimates of the oral and long-acting injectable agents. We calculated the dosing ratios to this dose of olanzapine and to the equivalent dose for chlorpromazine as a historical reference. Injectable haloperidol, 5 mg, was the reference for short-acting injectable agents. Study participants also rated their confidence in each estimate provided, as high (based on extensive experience; applies to most patients), moderate (some experience; probably applies to most patients), or low (limited experience or frequent exceptions based on clinical circumstances). Participants were instructed to give priority to efficacy over tolerability in dosing estimates.

Section B requested usual starting doses, typical target ranges, and usual maximum doses for the each oral or injectable agent (N=61). Brief, standardized clinical vignettes provided a consistent context for responses. Typically, vignettes were based on treatment of adult males with DSM-IV or ICD-10 schizophrenia, with ≥ 2 years of lifetime exposure to antipsychotics and not considered treatment refractory or intolerant. Section C sought dosing recommendations based on variance in demographic and clinical circumstances.

Survey Methods

Following review and approval of the study protocol by the Dalhousie University Health Sciences Research Ethics Board, each study participant provided written, informed consent for participation and public acknowledgment. In 2007–2008, partici-

TABLE 2. Clinical Dosing Equivalencies and Dosing Recommendations for Short-Acting Injectable Antipsychotics

Drug	N	Clinically Equivalent Dose (mg) ^a		Dosing Recommendations (mg) ^b				
				Initial Dose		Dose per Injection	Maximum Dose per 24 Hours	
		Median	IQR	Median	IQR	Range	Median	IQR
Chlorpromazine HCl	34	100	25	50	12	25–75	200	100
Clotiapine injectable	6	40	8	40	0	40–80	80	30
Fluphenazine HCl	17	5	0	5	0	5–10	20	5
Haloperidol lactate	38	5 (ref)	—	5	0	5–10	20	5
Loxapine HCl	7	25	0	25	4.5	25–50	75	15
Mesoridazine besylate	6	100	62	25	0	25–50	150	75
Olanzapine tartrate	39	10	0	10	0	10–15	20	5
Perphenazine USP	16	10	1	5	2	6–12	18	6
Prochlorperazine mesylate	4	22	6	5	1	5–12	12	5
Promazine HCl	8	100	50	50	0	50–100	200	75
Trifluoperazine HCl	6	5	1	3	1	4–9	9	4
Trifluopromazine HCl	3	60	5	25	5	30–55	68	8
Ziprasidone mesylate	25	20	8	10	5	20–40	40	0
Zuclopenthixol acetate	26	50	0	50	6	50–100	100	25

^a Respondents were asked what dose they consider to be clinically equivalent to a single, 5-mg intramuscular dose of haloperidol in treatment of the reference case, an adult man with DSM-IV schizophrenia not treated for 2 weeks, presenting with delusions, auditory hallucinations, agitation, poor cooperation, threatening behavior, and who is refusing oral medications. Median confidence regarding clinically equivalent dosing was reported as moderate for all agents except mesoridazine, prochlorperazine, and trifluopromazine, for which confidence was rated low.

^b Respondents were asked to indicate their usual initial intramuscular dose, the dose range per injection, and the maximum intramuscular dose per 24 hours for the reference case. Range of doses/injection reflects the median lower and upper doses of ranges recommended.

pants were sent the same study survey instrument electronically in two stages, based on the iterative Delphi method of consensus-building, a method that has been used extensively in social sciences and health research including mental health (26–28). This method provides for independent input by each participant at both stages, with anonymous, summary information provided at stage II to each participant based on the averaged, collective contributions from stage I. Summary information included the means (with standard deviations and coefficients of variation), medians (with ranges and interquartile ranges), and the median confidence levels of stage I responses regarding each drug, as well as the number of respondents per estimate. Minor adjustments for stage II included addition of clotiapine, as suggested by several participants, and removal of spiroperidol and pipothiazine undecylenate for lack of responses in stage I. We also modified section C to request dosing recommendations in the presence of common comorbid medical disorders (diabetes mellitus, ischemic heart disease, organic brain syndrome, substantial hepatic or renal impairment) identified by respondents in stage I.

Data Analysis

First, we evaluated associations of recommended oral doses averaged across all drugs as a continuous variable for each study participant versus a total of nine participant characteristics, including four continuous variables tested with linear regression (age, years of experience, antipsychotic research studies per participant, and peer-reviewed publications per participant), with contingency tables to evaluate four categorical variables (sex, country, majority of patients treated [in terms of diagnosis and race/ethnicity], and main career interest [research/clinical] of participants).

In addition, we sought recommendations for adjusting oral doses of antipsychotics based on the following patient demographic and clinical characteristics: sex, age, race or ethnicity, diagnosis, current clinical state, illness severity, illness duration, specific psychiatric comorbidity (substance use or anxiety disorders), medical comorbidity (ischemic cardiac disease, clinically hepatic or renal impairment, diabetes mellitus, delirium, or de-

mentia), abnormally high or low body weight (based on standard BMI criteria provided), and type of oral formulation. For each factor, we evaluated the proportion of participants recommending a dose change and calculated median percentage changes in dose.

We summarized reported estimates of clinical dosing equivalents among agents and clinical circumstances, based on comparison to standard treatments, as reported in stage II. As median and mean oral dosage equivalency estimates were very similar in our preliminary assessment ($r=0.997$, $p<0.0001$; slope=1.01 [95% CI= 0.985–1.04]), only medians with interquartile range (IQR) are reported for simplicity and to limit the impact of potential extreme or outlier values. IQR represents the midpoint of the difference between the 25th and 75th percentile values. Coefficient of variation ($SD/mean \times 100$) was used to indicate consensus in final recommendations and was defined empirically as high ($\leq 25\%$), moderate (26%–33%), or relatively low ($>33\%$). For oral agents, equivalency ratios were calculated for olanzapine, the reference treatment, and for chlorpromazine. Statistical analyses employed commercial software (Stata.8®, Stata Corp, College Station, Tex.; Statview.V®, SAS Corp, Cary, N.C.; and SPSS 15.0 for Windows, Chicago).

Results

Participants

We obtained agreement to participate from 46 of 111 candidates (41.4%); 43 of these participants (93.5%; 32 researchers, 11 clinicians), representing a wide geographic distribution and 18 countries, completed both stages of the Delphi process. The participant group was mostly male (91%). The mean age of the group was 49 years ($SD=10$). Participants had a mean of 23 years ($SD=10$) of experience with antipsychotics and had been involved in a median of 15 studies with 30 antipsychotic peer-reviewed

TABLE 3. Clinical Dosing Equivalencies and Dosing Recommendations for Long-Acting Injectable Antipsychotics

Drugs	N	Dosing Recommendations ^b								
		Clinically Equivalent Dose ^a (mg/injection)		Dosing Interval (days)		Initial Dose (mg/injection)		Target dose (mg/injection)	Maximum Dose (mg/injection)	
		Median	IQR	Median	IQR	Median	IQR	Range	Median	IQR
Olanzapine oral (mg/day)	—	20 (ref)	—							
Clopenothol decanoate	7	300	58	14	2	100	6	175–300	500	100
Flupenthixol decanoate	21	40	9	14	1	20	1	20–60	80	24
Fluphenazine decanoate	37	25	0	14	4	12	3	25–50	60	12
Fluphenazine enanthate	15	25	0	14	0	15	6	25–50	60	12
Fluspirilene	6	6.0	1	7	0	2	1	2–6	8	1
Haloperidol decanoate	37	150	25	28	0	50	0	50–150	200	7
Perphenazine enanthate	10	100	9	14	0	50	27	67–200	200	8
Pipotiazine palmitate	9	100	0	28	4	50	8	50–120	200	33
Risperidone microspheres	36	50	6	14	0	25	0	25–50	50	12
Zuclopenthixol decanoate	24	200	9	14	4	100	8	133–300	400	67

^a Respondents were asked what dose and interval they considered clinically equivalent to oral olanzapine, 20 mg/day, in the treatment of the reference case, a moderately symptomatic adult man with DSM-IV schizophrenia, not considered treatment-refractory with ≥ 2 years of antipsychotic treatment. The reported clinically equivalent doses are adjusted to correspond to the median dosing interval. Confidence in the clinically equivalent dose was moderate for all agents.

^b Respondents were asked to indicate their usual dosing interval, initial dose, target dose range, and maximum dose for the reference case, who differed from the above description in that recent use of an oral antipsychotic had been intermittent due to poor treatment adherence. The oral antipsychotic and dose were not specified. Initial and maximum doses are adjusted to match the median dosing intervals. Target dose range reflects the median lower and upper doses of the ranges recommended.

publications. For their primary interest, 58% specifically indicated schizophrenia, with 35% more broadly indicating psychotic or major mood disorders. Their experience was primarily with Caucasian patients (72%), East-Asian (14%), or patients of various races (Asian, black, Caucasian including Hispanic, 14%).

Geographically, most respondents were from North America (U.S. [N=10] or Canada [N=4]) or Western Europe (Italy [N=4], Spain [N=4], Austria [N=2], Denmark [N=2], Germany [N=2], Portugal [N=2], Belgium [N=1], Finland [N=1], or United Kingdom [N=1]). Other regions included Japan (N=3), Turkey (N=2), and India, Israel, People's Republic of China, Republic of Korea, and Taiwan (N=1 each).

Delphi Effect and Consensus

Each stage of the Delphi process required participants to complete up to 59 clinical equivalency estimates and 191 dosing recommendations. The consistency of equivalency estimates improved as the average coefficient of variation decreased from 57% in stage I to 33% in stage II (paired t test between study stages: $t=7.20$, $df=58$, $p<0.0001$). Consensus also improved among dosing recommendations (starting, target, and maximum), with moderate or high consensus (coefficient of variation $<33\%$) rising from 29% to 47% between stages I and II. Final consensus, based on moderate or high median levels of agreement (coefficient of variation $<33\%$), was 76.3% overall for equivalency estimates (long-acting injected agents: 90%; oral agents: 83%; short-acting injected agents: 46%) and 67% for all dosing recommendations (oral agents: 69%; short-acting injected agents: 67%; long-acting injected agents: 60%). Median dosing recommendations (mg/day) were 5.8% lower in

stage II, reflecting changes in 28.7% (N=74 of 258) of initial recommendations.

Clinically Equivalent Dose Estimates and Recommendations

Clinically equivalent antipsychotic dosing recommendations were obtained for oral (N=36 [Table 1]), short-acting injectable (N=13 [Table 2]), and long-acting injectable (N=10 [Table 3]) formulations. Based on data reported (Table 1), the overall mean median starting dose for oral antipsychotics in olanzapine equivalents was 4.8 mg/day (IQR=1.4); the overall target dose range (mean median of lower and upper bounds of ranges) was 10.2 to 25.5 mg/day; and the overall mean median maximum dose for oral antipsychotics in olanzapine equivalents was 30.9 mg/day (IQR=7.5).

There were no significant differences in estimates of mean or median clinical dosing equivalencies among all oral or parenteral antipsychotics between research (N=32) and clinical (N=11) experts. Overall, there was strong agreement between participant types regarding clinically equivalent dosing estimates for all agents and formulations (Pearson $r=0.979$). Findings were similar for dosing recommendations of oral agents ($r=0.991$) and for parenteral preparations ($r=0.959$; all $p<0.0001$).

Factors Associated With Dosing Recommendations

Preliminary bivariate analyses for effects on starting and maximum recommended daily oral doses related to eight participant characteristics (sex, age, years of experience, antipsychotic studies and publications/person, country, major diagnostic type of patients treated, and main career interest [research/clinical]) revealed no significant associations. Since no factor was sustained as important in these

TABLE 4. Factors for Which Antipsychotic Dosing Changes Are Recommended^a

Factors	N	Respondents Recommending Dose Change (%)	Recommended Dose Change (%)	
			Median	IQR
Child (6–puberty)	40	95	–60	10
Elderly (≥65 yrs)	43	98	–50	0
Hepatic function impaired	43	79	–45	12
First episode (<6 months treatment)	42	93	–30	15
Adolescent	41	83	–30	15
Organic brain syndrome	43	63	–30	18
Renal function impaired	43	53	–30	15
Mild severity	42	74	–25	5
Bipolar: depressed	43	65	–25	9
Bipolar: euthymic	43	63	–25	15
Ischemic heart disease	43	49	–25	16
Underweight (BMI<18.5 kg/m ²)	42	62	–20	13
Short-acting intramuscular agent	42	45	–20	15
Asian (vs. Caucasian)	40	50	–20	10
Female	43	39	–10	10
Diabetes mellitus	43	23	–10	10
Severe psychosis and dysfunction	43	74	+25	3

^a Reported are numbers of responses and percentage of respondents recommending dosing changes, ranked by median magnitude and direction (decrease or increase) of recommended daily oral dose adjustments, for factors deviating from the reference case, a moderately symptomatic adult Caucasian man of normal weight with DSM-IV schizophrenia, not considered refractory, with >2 years of antipsychotic treatment but untreated for >1 month. Other patient characteristics not considered to require dosing adjustment included being overweight (BMI 25–30 kg/m²) or obese (BMI >30.0); being black or Hispanic; ≥15 years of illness and antipsychotic drug use; being hospitalized versus ambulatory; disorders other than schizophrenia (schizoaffective, delusional, manic or mixed states of bipolar disorder, or unspecified psychosis); comorbid substance use or anxiety disorders; average clinical quality of prior antipsychotic treatment responses; rapid-dissolving tablet or oral liquid formulations.

initial analyses (not shown) we did not pursue multivariate modeling.

Several patient factors did affect dosing recommendations (Table 4). As expected, age had a major effect in that recommended median daily oral antipsychotic doses were 60%, 30%, and 50% lower in children, adolescents, and the elderly, respectively, than in young adults. Selected medical comorbidities (e.g., diabetes, heart disease, hepatic or renal impairment, organic brain syndrome) also led to 10%–45% lower recommended median daily oral doses relative to adult patients without such illnesses. Respondents recommended an average of 20% lower daily antipsychotic doses for East-Asian versus Caucasian patients, even though dosing recommendations for the participant's predominant race/ethnicity of patients treated was not significantly associated with dosing recommendations (data not shown). Recommended daily doses averaged 10% lower for adult women than for men. For underweight patients, based on standard BMI criteria (<18.5 kg/m²), recommended doses were 20% lower than for normal weight patients (BMI=18.5–24.9 kg/m²) but were not affected significantly for overweight patients (BMI≥25 kg/m²). Dosing recommendations were not affected by comorbid anxiety or substance use disorders.

Several factors related to psychiatric illness were associated with dosage modifications, although dosing was similar for most forms of psychotic or manic illness. However, bipolar depression or long-term prophylactic treatment of currently euthymic bipolar disorder patients called for dose reductions averaging 25% below the similar recom-

mendations for acute mania or exacerbated schizophrenia. Severe, acute psychotic illness or a history of unsatisfactory treatment response led to recommended increases of daily antipsychotic dose by an average of 25%, whereas mild symptoms and first-episode of psychotic illness led to 25%–30% lower recommended doses than for repeatedly acutely psychotic patients, with no distinction between acute and chronic illnesses. There were no appreciable differences in recommended dosing for hospitalized versus ambulatory patients diagnosed with reasonably clinically stable, chronic schizophrenia. Drug formulations also had no effect on recommended doses, except that dosage reduction by 20% was recommended for short-acting injected preparations relative to oral preparations (Table 4).

Discussion

Broadly representative and plausible recommendations of clinically equivalent doses for antipsychotic drugs are needed to guide clinical dosing decisions, design of research studies, and interpretation of research findings (2, 4, 5, 22–25). Accordingly, this study employed a Delphi, two-stage, international survey of experienced and expert clinical and research colleagues to gain consensus estimates of clinically equivalent doses (compared to oral olanzapine or short-acting injectable haloperidol as standards). Dosing recommendations (starting dose, typical target range, and maximum daily doses) of currently clinically employed oral and parenteral antipsychotics also were sought using the same method along with consensus

recommendations for their modification under specific clinical circumstances.

This is a first application of the otherwise widely employed Delphi method for seeking consensus to estimate equivalent doses of antipsychotics. Effectiveness of the two-stage Delphi method used is indicated by decreases in the variance of dose estimates between survey stages, and by achieving an average rate of 76% consensus in final (stage II) clinical equivalency estimates and 67% for all dosing recommendations.

Over several decades, there have been efforts to estimate equivalent doses of antipsychotic and other psychotropic drugs. Typically, these recommendations have considered limited ranges of agents and made use of findings from flexible-dose trials with varying ranges of permitted doses and clinically determined doses (13–18). Such recommendations risk confounding-by-indication and regression-to-mean artifacts and have led to sometimes strikingly inconsistent recommendations. Notably, the World Health Organization (WHO) system of expert consensus-based recommendations of defined daily doses for antipsychotics identified 10 mg/day of olanzapine as the average maintenance dose for adult patients diagnosed with schizophrenia (18, 29); this is a conservative dose for many psychotic patients (2, 3, 7). We used 20 mg/day of olanzapine as a standard reference treatment on which to base the reported clinically equivalent dosing estimates. Based on this difference in recommended doses of olanzapine, it is not surprising that the average equivalent dose among oral agents was 50% higher (1.5 ± 1.6 times greater) in this study than in WHO-defined daily dose recommendations, although these sets of equivalent doses are strongly correlated ($r=0.920$).

Fixed-dose, randomized trials involving multiple active comparators at a wide range of doses are required to estimate dosing equivalencies objectively and provide scientifically secure dosing recommendations. Considering the highly varied indications for antipsychotics and great heterogeneity of patients and their treatment responses, required studies would need to be either very large or repeated several times in dissimilar patient populations. Based on the limited available fixed-dose data, Davis and Chen (17) attempted in 2004 to estimate the near maximal effective dose of antipsychotics by generating dose-response curves. Their findings demonstrate the limitations associated with this method. For oral antipsychotics, the computed near-maximally effective dose varied by 50% to 300% for only seven antipsychotics, with striking variance among individual dose responses for most drugs. For four agents they could only provide a threshold dose, with reference to which the near maximal effective dose was estimated to be above or below. For these drugs, limitations in the data failed to indicate at which dose the response curve plateaus. In only three cases were they able to report a single oral dose as the “near maximal effective dose” (amisulpride, 200 mg; aripiprazole, 10 mg; and risperi-

done, 4 mg). These estimates were based on findings with significant heterogeneity or minimal datapoints. With these limitations, it is not possible currently to determine clinically equivalent doses of antipsychotics firmly based on randomized, controlled, and blinded fixed-dose trials involving more than one drug, a placebo, and patients of specific types. This state of current knowledge is not surprising considering the heterogeneity of clinical presentations and of treatment responses, even among patients with nominally identical DSM or ICD diagnoses, long recognized by clinicians and researchers, and elegantly noted by Davis and Chen (17). Despite these limitations and using the midpoint dose (estimated median) of the ranges reported by Davis and Chen (17), we found a strong correlation between their near-maximally effective doses and the equivalent doses in our survey among 10 oral antipsychotics common to both investigations (Pearson's $r=0.890$, $p<0.0001$).

Other proposals to establish drug potency equivalents include use of plasma or serum concentrations of antipsychotic drugs and their major active metabolites, or modern brain imaging methods to estimate levels of receptor occupancy, usually involving competition for dopamine D_2 receptors labeled with positron-emitting, selective radioligands (30–32). Although theoretically attractive, such methods are costly and technically challenging. At best they provide indirect correlates to clinical response that may be especially questionable with respect to the limited D_2 -antagonistic actions of some commonly used, second-generation antipsychotic agents (2, 30–33).

The present study identified several patient characteristics leading to recommended dosage adjustments (Table 4), notably including substantial lowering of doses for geriatric and pediatric patients, and increases for cases involving severe psychotic symptoms and dysfunction. These dosing recommendations appear to have face validity in that they are consistent with currently standard clinical practices. The specific consensus recommendation to reduce doses of antipsychotic drugs for East Asian patients by approximately 20% relative to Caucasians (Table 4) is consistent with some but not other reports concerning comparative dosing across races, and was not associated with the predominant race/ethnicity of patients usually treated by study participants, leaving the question unresolved (25, 34, 35).

This study has several limitations. Although the range of geographic sites and professional experiences represented is quite broad, several regions of the world, especially Central and South America, much of Eastern Europe, and parts of the Middle East, Africa, and south-central Asia are notably unrepresented, and the sample comprised mostly male physicians despite efforts to recruit more women. A more substantive limitation is the lack of objective standards by which to select standard comparator doses, and to verify what are essentially clinical impressions, even though provided collectively and systemati-

cally by experts. Experience-based dosing opinions are susceptible to many influences, including uncritically accepted local dosing practices, inaccurate representations of personal practices, or inaccurate dosing recommendations by manufacturers in the regulatory approval process. In addition, the results assume, unrealistically, that clinical antipsychotic dosing is constant and uniform among diagnoses, under changing and typically unstable clinical conditions, and in often subtly differing forms or levels of symptomatic severity. In addition, several uncommonly used agents received relatively few responses from study participants (Table 1). Median doses and their variance are reported so as to minimize effects of outlier values, and they were remarkably similar to mean doses. Moreover, there is a tacit, but unrealistic, pharmacological assumption of linearity of dosing across a broad range of doses and across many dissimilar drugs that cannot be captured adequately with an estimated, consensus ratio of potency to a single, selected dose of a standard agent such as olanzapine or chlorpromazine (2, 14, 17; Tables 1–3). Despite these and other limitations, we present the findings of this international survey as a representation of substantial and systematically acquired expert consensus. The findings should provide at least approximate and general guidelines to support clinical dosing in adults as well as planning and interpretations of experimental therapeutics trials and other research studies.

In conclusion, the reported findings arise from a large, systematic, international survey using Delphi methods to develop consensus. It provides general guidelines for approximately clinically equivalent recommended doses of a broad range of clinically employed, modern and older antipsychotics, including both oral and parenteral formulations. The study also provides recommendations from clinical and research experts on modification of dosing based on specific demographic or clinical characteristics of patients for whom antipsychotics are commonly employed.

Received June 8, 2009, revision received Oct. 5, 2009; accepted Nov. 30, 2009 (doi: 10.1176/appi.ajp.2009.09060802). From the Department of Psychiatry, College of Pharmacy, and School of Nursing, Dalhousie University; Department of Psychiatry, Harvard Medical School and International Bipolar & Psychotic Disorders Research Consortium, McLean Division of Massachusetts General Hospital, Boston. Address correspondence and reprint requests to Dr. Gardner, Department of Psychiatry & College of Pharmacy, Dalhousie University, QEII HSC, Abbie Lane Bldg. 7517, 5909 Veterans' Memorial Lane, Halifax, N.S., Canada, B3H 2E2; david.gardner@dal.ca (e-mail).

Dr. Gardner has provided training to employees of AstraZeneca; has participated in advisory boards with Eli Lilly, Janssen-Ortho, and Pfizer Corporations; and leads a project funded by Pfizer. He is not a member of any speakers bureaus. Dr. Centorrino was an advisor to Janssen and was a member of speakers bureaus for AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Janssen, Johnson & Johnson, and Pfizer Corporations until December 2009. Dr. Baldessarini has recently been a consultant or investigator-initiated research collaborator with AstraZeneca, Auritec, Biotrofix, Janssen, JDS-Noven, Lilly, Luitpold, NeuroHealing, Novartis, Pfizer, and SK-BioPharmaceutical Corporations; he is not a member of pharmaceutical speakers bureaus. Dr.

Murphy and Ms. O'Donnell report no financial relationships with commercial interests. None of the authors or their immediate family members holds equity positions in biomedical or pharmaceutical corporations.

Supported by the Department of Psychiatry Research Fund, Dalhousie University (to Dr. Gardner), a grant from the Bruce J. Anderson Foundation, and by the McLean Private Donors Psychopharmacology Research Fund (to Dr. Baldessarini).

The authors thank study participants (all of whom consented to be named): Drs. A. Carlo Altamura (Italy), Jose A. Apud (U.S.), A. George Awad (Canada), Ross J. Baldessarini (U.S.), Corrado Barbui (Italy), Daniel Casey (U.S.), Franca Centorrino (U.S.), Siow-Ann Chong (Singapore), Young-Chul Chung (Republic of Korea), Benedicto Crespo-Facorro (Spain), John M. Davis (U.S.), Marc De Hert (Belgium), W. Wolfgang Fleischhacker (Austria), David Gardner (Canada), John Geddes (United Kingdom), Birte Glenthøj (Denmark), Donald Goff (U.S.), Ricardo Gusmão (Portugal), Giuseppe Imperadore (Italy), Philip G. Janicak (U.S.), Yasuhiro Kaneda (Japan), Alain Labelle (Canada), Hsien-Yuan Lane (Taiwan), Stefan Leucht (Germany), John Luo (U.S.), Stephen R. Marder (U.S.), Massimo Mauri (Italy), Vicente Molina (Spain), Dieter Naber (Germany), Evaristo Nieto (Spain), Kensuke Nomura (Japan), Dost Öngür (U.S.), Linda Peacock (Denmark), Gary Remington (Canada), Christian Simhandl (Austria), Rael Strous (Israel), Takefumi Suzuki (Japan), Jari Tiihonen (Finland), JK Trivedi (India), Eduard Vieta (Spain), Miguel Xavier (Portugal), A. Elif Anil Yagcioglu (Turkey), and Nevzat Yuksel (Turkey).

References

1. Leslie DL, Rosenheck RA: From conventional to atypical antipsychotics and back: dynamic processes in the diffusion of new medications. *Am J Psychiatry* 2002; 159:1534–1540
2. Baldessarini RJ, Tarazi FI: Pharmacotherapy of psychosis and mania, in Goodman and Gilman's *The Pharmacological Basis of Therapeutics*, 11th ed. Edited by Brunton LL, Lazo JS, Parker KL. New York, McGraw-Hill, 2005, pp 461–500
3. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK (Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators): Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. *N Engl J Med* 2005; 353:1209–1223
4. Gardner DM, Baldessarini RJ, Warcha P: Modern antipsychotic drugs: a critical overview. *CMAJ* 2005; 172:1703–1711
5. Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S: Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. *Am J Psychiatry* 2006; 163:185–194
6. Jones PB, Davies L, Barnes TR, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW: Randomized controlled trial of effect on quality of life of second-generation versus first generation antipsychotic drugs in schizophrenia. *Arch Gen Psychiatry* 2006; 63:1079–1087
7. Centorrino F, Cincotta SL, Talamo A, Fogarty KV, Guzzetta F, Saadeh MG, Salvatore P, Baldessarini RJ: Hospital use of antipsychotic drugs: polytherapy. *Compr Psychiatry* 2008; 49:65–69
8. Domino ME, Swartz MS: Who are the new users of antipsychotic medications? *Psychiatr Serv* 2008; 59:507–514
9. Goudie AJ, Cole JC: Switching antipsychotics; antipsychotic tolerance, withdrawal and relapse: unresolved issues and research implications. *J Psychopharmacol* 2008; 22:815–817
10. Lewis S, Lieberman J: CATIE and CUTLASS: can we handle the truth? *Br J Psychiatry* 2008; 192:161–163
11. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM: Second-generation versus first-generation antipsychotic drugs for schizophrenia: meta-analysis. *Lancet* 2009; 373:31–41

12. Parks J, Radke A, Parker G, Foti ME, Eilers R, Diamond M, Svendsen D, Tandon R: Principles of antipsychotic prescribing for policy makers, circa 2008. Translating knowledge to promote individualized treatment. *Schizophr Bull* 2009; 35:931–936
13. Davis JM: Comparative doses and costs of antipsychotic medication. *Arch Gen Psychiatry* 1976; 33:858–861
14. Baldessarini RJ, Cohen BM, Teicher MH: Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. *Arch Gen Psychiatry* 1988; 45:79–91
15. Rijcken C, Monster T, Brouwers J, de Jong-van den Berg LT: Chlorpromazine equivalents versus defined daily doses: how to compare antipsychotic drug doses? *J Clin Psychopharmacol* 2003; 23:657–659
16. Woods SW: Chlorpromazine equivalent doses for the newer atypical antipsychotics. *J Clin Psychiatry* 2003; 64:663–667
17. Davis JM, Chen N: Dose response and dose equivalence of antipsychotics. *J Clin Psychopharmacol* 2004; 24:192–208
18. Nosè M, Tansella M, Thornicroft G, Schene A, Becker T, Veronese A, Leese M, Koeter M, Angermeyer M, Barbui C: Is the defined daily dose system a reliable tool for standardizing antipsychotic dosages? *Int Clin Psychopharmacol* 2008; 23:287–290
19. Bezchlibnyk-Butler KZ, Jeffries JJ: *Clinical Handbook of Psychotropic Drugs*, 17th rev ed. Seattle, Hogrefe & Huber, 2007
20. Leucht S, Arbter D, Engel RR, Kissling W, Davis JM: How effective are second-generation antipsychotic drugs? Meta-analysis of placebo-controlled trials. *Mol Psychiatry* 2009; 14:429–447
21. Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, Asenjo Lobos C, Schwarz S, Davis JM: Meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. *Am J Psychiatry* 2009; 166:152–163
22. Dewan MJ, Koss M: The clinical impact of reported variance in potency of antipsychotic agents. *Acta Psychiatr Scand* 1995; 91:229–232
23. Owen RR, Fischer EP, Kirchner JE, Thrush CR, Williams DK, Cuffel BJ, Elliott CE, Booth BM: Clinical practice variations in prescribing antipsychotics for patients with schizophrenia. *Am J Med Qual* 2003; 18:140–146
24. Sohler NL, Walkup J, McAlpine D, Boyer C, Olsson M: Antipsychotic dosage at hospital discharge and outcomes among persons with schizophrenia. *Psychiatr Serv* 2003; 54:1258–1263
25. Sim K, Su HC, Fujii S, Yang SY, Chong MY, Ungvari G, Si T, He YL, Chung EK, Chan YH, Shinfuku N, Kua EH, Tan CH, Sartorius N: High-dose antipsychotic use in schizophrenia: a comparison between the 2001 and 2004 Research on East Asia Psychotropic Prescription (REAP) studies. *Br J Clin Pharmacol* 2009; 67:110–117
26. Dalkey NC: The Delphi Method: an experimental study of group opinion: US Air Force-RAND Project. Santa Monica, Calif, RAND Corp, 1969
27. Hasson F, Keeney S, McKenna H: Research guidelines for using the Delphi survey technique. *J Adv Nurs* 2001; 32:1008–1015
28. Langlands RL, Jorm AF, Kelly CM, Kitchener BA: First aid recommendations for psychosis: using the Delphi method to gain consensus between mental health consumers, carers, and clinicians. *Schizophr Bull* 2008; 34:435–443
29. World Health Organization Collaborating Centre for Drug Statistics Methodology: ATC/DDD Index 2009. <http://www.whocc.no/atcddd/>
30. Mauri MC, Volonteri LS, Colasanti A, Fiorentini A, De Gaspari IF, Bareggi SR: Clinical pharmacokinetics of atypical antipsychotics: critical review of the relationship between plasma concentrations and clinical response. *Clin Pharmacokinet* 2007; 46:359–388
31. Tauscher J, Hussain T, Agid O, Verhoeff NPLG, Wilson AA, Houle S, Remington G, Zipursky RB, Kapur S: Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics. *Am J Psychiatry* 2004; 161:1620–1625
32. Pani L, Pira L, Marchese G: Antipsychotic efficacy: relationship to optimal D2-receptor occupancy. *Eur Psychiatry* 2007; 22:267–275
33. Ito H, Arakawa R, Takahashi H, Takano H, Okumura M, Otsuka T, Ikoma Y, Shidahara M, Suhara T: No regional difference in dopamine D2 receptor occupancy by the second-generation antipsychotic drug risperidone in humans: a positron emission tomography study. *Int J Neuropsychopharmacol* 2009; 12:667–675
34. Lin K-M, Poland R, Nuccio I, Matsuda K, Hathuc N, Su TP, Fu P: Longitudinal assessment of haloperidol dosage and serum levels and concentrations in Asian and Caucasian schizophrenic patients. *Am J Psychiatry* 1989; 146:1307–1311
35. Pi EH, Simpson GM: Cross-cultural psychopharmacology: current clinical perspective. *Psychiatr Serv* 2005; 56:31–33